

2023 EFPIA DISCLOSURE (inc. Vaccines Europe)

Date of publication:

	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier <i>OPTIONAL</i>	Contribution to costs of Events			Fee for service and consultancy			
						Donations and Grants to HCOs and POs	Sponsorship agreements with HCOs POs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees		Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the
<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
HCPs						N/A	N/A					
	Prof Peter Kremsner	Tübingen	Germany	Universitätsklinikum Tübingen, Postfach 2669, 72016 Tübingen, Deutschland		N/A	N/A			11.000,00 €	Comment *	
	Prof Sergiusz Jozwiak	Warschau	Poland	Warschau Universität, Krakowskie Przedmieście 26/28, 00-927 Warschau, Polen		N/A	N/A			2.450,00 €	Comment *	
	Ahmed Geneid	Helsinki	Finland	HUS, ENT-Head and Neck Surgery, Phoniatics Department, Maistraatinportti 2, P.O.B 250, HUS						6.096,00 €	Comment *	
						N/A	N/A					
<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
Aggregate amount attributable to transfers of value to such Recipients						N/A	N/A			11.000,00 €	Comment *	
Number of Recipients in aggregate disclosure						N/A	N/A			1		
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed						N/A	N/A					
<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
HCOs												
<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
Aggregate amount attributable to transfers of value to such Recipients						N/A	N/A					
Number of Recipients in aggregate disclosure						N/A	N/A					
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed						N/A	N/A					
<i>INDIVIDUAL NAMED DISCLOSURE - one line per PO (i.e. all transfers of value during a year for an individual PO will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
POs	Name	Description of the transfer of value										
<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
Aggregate amount attributable to transfers of value to such Recipients						N/A	N/A					
Number of Recipients in aggregate disclosure						N/A	N/A					
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed						N/A	N/A					
AGGREGATE DISCLOSURE												
Transfers of Value re Research & Development as defined												
ToV related to R&D		24.450,00 €										Comment *

* These Transfer of Values were done by Nobelpharma Co. Ltd. Japan